Abbott Laboratories vs. Acadia Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc. (ACAD) comes out ahead, leading on 5 of 9 compared factors.
Size & Scale
| ABT | ACAD | |
|---|---|---|
| Market Cap | $175.27 billion | $3.56 billion |
| Revenue (TTM) | $46.59 billion | $1.14 billion |
| Net Income (TTM) | $5.42 billion | $380.48 million |
ABT leads on 3 of 3 size & scale factors.
Valuation
| ABT | ACAD | |
|---|---|---|
| P/E Ratio | 32.78 | 9.27 |
| Price / Book | 3.39 | 2.73 |
| Price / Sales | 3.76 | 3.13 |
ACAD leads on 3 of 3 valuation factors.
Profitability
| ABT | ACAD | |
|---|---|---|
| Net Margin | 11.65% | 33.42% |
| Return on Equity | 10.48% | 29.12% |
ACAD leads on 2 of 2 profitability factors.
Dividend
| ABT | ACAD | |
|---|---|---|
| Dividend Yield | 2.49% | — |
| Payout Ratio | 81.55 | — |
ABT and ACAD split the dividend factors evenly.
Risk & Sentiment
| ABT | ACAD | |
|---|---|---|
| Short Interest | 0.57% | 5.74% |
ABT leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABT overview, ABT financials, ACAD overview, ACAD financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.